

Please type a plus sign (+) inside this box → □

PTO/SB/08A (10-96)  
 Approved for use through 10/31/99. OMB 0651-0031  
 Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form-1449A/PTO  <h2 style="text-align: center;">SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2>		Complete if Known	
Application Number	10/044.807		
Filing Date	Jan 11, 2002		
First Named Inventor	Hu		
Group Art Unit	1651		
Examiner Name	Sheridan Swope		
Attorney Docket Number	LEX-0298-USA		
Shee <u>1</u> of <u>1</u> (Use as many sheets as necessary)			

### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document	Name of Patentee or Applicant of Cited Document	Date of Publication of cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code <sup>2</sup> (if known)			

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Name of Patentee or Applicant of Cited Document	Date of Publication of cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
85	CK	WO 99 31236 A	GENSET	06-24-1999		
85	CL	WO 00 00610 A	INCYTE PHARMA	01-06-2000		
85	CM	WO 01 57188 A	HYSEQ, INC.	08-09-2001		
85	CN	WO 01 62928 A	CURAGEN INC.	08-30-2001		
85	CO	WO 01 11074 A	CLEVELAND CLINIC	02-15-2001		

### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
85	CP	DATABASE EMBL 13 September 1999, BOUGUELERET L. ET AL.: "Extended human secreted protein sequence, SEQ ID NO. 148" Database accession no. AAY35899, XP002221259	
85	CQ	DATABASE EMBL 'Online! 13 September 1999, BOUGUELERET L. ET AL.: "Extended human secreted protein sequence, SEQ ID NO. 47" Database accession no. AAX97583, XP002222650	
85	CR	DATABASE EMBL, 11 January 2002, TANT YT ET AL.: "Human BPTI/Kunitz inhibitor family homologue cDNA, SEQ ID NO: 238", Database accession no. ABA08462, XP002221371.	
85	CS	DATABASE EMBL, 10 December 2001, VERNET CAM ET AL.: "Human novel KIAA1233-lik3 protein, NOV-2a" Database accession no. AAE10609, XP002221372	
85	CT	DATABASE EMBL, 8 August 2001, HIROHATA S ET AL.: "Homo sapiens ADAM-TS related protein 1 (ADAMTSR1) Mrna", Database Accession no. AF176313, XP002221373	
85	CU	International Search Report	

Examiner Signature <u>Swope</u>	Date Considered	1/28/03
---------------------------------	-----------------	---------

\*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.